Sponsors

Fluxergy acquires HomeLab technology from InnaMed

Fluxergy, a medical diagnostic company focused on multiplex, multimodal point-of-care testing, has announced that it has acquired certain employees and assets and licensed electrochemical biosensing technology from InnaMed, Inc. including the HomeLab device and software.

InnaMed built a platform for decentralised blood testing through electrochemical biosensor technology with the HomeLab device and analysis software. The license of this technology will further expand the Fluxergy platform’s microfluidic portfolio with the incorporation of InnaMed’s electrochemical technology.

Currently, the Fluxergy Analyzer utilises four major sensor and fluidics systems: fluorescence, colorimetry, electrical potentiometry, and imaging cytometry. This allows for seamless integration of InnaMed’s core technology into the architecture of the Fluxergy Analyzer, Test Card, and the Fluxergy Works software platform.

InnaMed’s technology supports Fluxergy’s goal of developing a rapid basic metabolic panel (BMP). Common biomarkers like glucose, electrolytes, hormones, liver proteins, and cardiac proteins are detectable using electrochemical sensing. This presents new opportunities for assay developers using the Fluxergy’s open platform model, a system which allows partners to integrate custom assays onto Fluxergy’s POC platform while utilising their scalable manufacturing facilities.

“Fluxergy envisions giving clinicians, healthcare providers, and laboratory professionals access to as many basic and specialized laboratory tests as possible from a single, decentralized platform; that is why we continue to grow our technological capabilities and detection modalities,” said Fluxergy President Tej Patel. “We are also excited to bring on key members of InnaMed’s talented team as consultants, in addition to its innovative technology, to continue pushing the boundaries of point-of-care.”

With the addition of the new technologies, Fluxergy plans to expand its detection capabilities to small molecule and clinical chemistries in human health, equine and small animal veterinary medicine, and other industries that can benefit from cost-effective analyte detection.

For more information visit fluxergy.com.

 

Latest Issues

RSM / Path Soc 2026 Winter Meeting

The Royal Society of Medicine, 1 Wimpole St, London, W1G 0AE
20 - 21 January, 2026

BIVDA Regulatory Affairs Seminar

Grand Hotel, Birmingham
10 - 11 February, 2026

BDIAP Molecular Pathology Study Day

10 Union Street, London, SE1 1SZ
2 March, 2026

USCAP 115th Annual Meeting

Henry B. González Convention Center, San Antonio, Texas, USA
21 - 26 March, 2026

Microbiology Society Annual Conference 2026

ICC Belfast, Northern Ireland
13 - 16 April, 2026